Vigonvita Life Sciences Co., Ltd. announced it has received a filing notice from the China Securities Regulatory Commission (CSRC) approving its H-share full-circulation application. The approval covers the conversion of 100.22 million unlisted domestic shares held by 10 existing shareholders into H shares.

Upon completion of the share conversion and subject to listing approval from Hong Kong Exchanges and Clearing Limited, the newly converted H shares will be admitted to trading on the Main Board of The Stock Exchange of Hong Kong. The CSRC filing notice remains valid for 12 months; should the conversion and listing extend beyond that period, the company must submit an updated filing.

Detailed implementation arrangements—including the conversion timetable—have yet to be finalized. Vigonvita stated it will release further updates in accordance with Hong Kong’s Listing Rules and inside-information provisions. The conversion process also requires additional procedures and approvals from both mainland and Hong Kong regulators.

The board is chaired by Dr. Tian Guanghui, who also serves as executive director, chief executive officer and general manager. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.